<DOC>
	<DOCNO>NCT02640495</DOCNO>
	<brief_summary>The spread artemisinin resistant falciparum malaria present new challenge control treatment malaria . Loss ring stage susceptibility artemisinins might jeopardize use parenteral artesunate first line drug treatment severe falciparum malaria . The purpose study assess effect artemisinin resistance ( define Kelch13 mutation know functional significance ) P. falciparum malaria require parenteral artesunate treatment lactate clearance parameter .</brief_summary>
	<brief_title>Artemisinin Resistance In Malaria Treated With IV Artesunate</brief_title>
	<detailed_description>The investigator propose multi-center observational study assess effect artemisinin resistance ( define presence relevant Kelch13 mutation ) efficacy parenteral artesunate treatment malaria , stratify disease severity admission . The patient receive standard intravenous treatment severe malaria ( parenteral artesunate ) . Primary endpoint plasma lactate concentration 12 hour proportion plasma lactate start treatment . Secondary endpoint improvement Glasgow Blantyre Coma Scores indicator neurological recovery deterioration , parasite clearance rate , time resolution fever , development new severity neurological sign treatment , development severe anemia , renal hepatic injury , total duration hospitalization , outcome pregnancy pregnant female patient , mortality rate necessity treat antibiotic , need renal replacement therapy , mechanical ventilation , blood transfusion rescue treatment . On admission blood take determination genetic marker antimalarial resistance ( include Kelch13 mutation know functional significance ) vitro sensitivity test artemisinins antimalarial . Additional blood sample use measure plasma organic acid biomarkers severe falciparum malaria measure mass spectrometry . Difference kinetics acid additional endpoint . Difference transcriptome p. falciparum assess RNA measurement baseline 3 timepoints treatment . The propose site Vietnam Cambodia chosen base prevalence artemisinin resistant falciparum malaria , incidence severe malaria local experience participate clinical trial . Interim analysis : To ensure timely recognition effect artemisinin resistance outcome malaria treat parenteral artesunate , interim analysis perform inclusion 60 patient one malaria transmission season ( whatever come first ) . An independent Data Safety Board ass whether difference outcome infection artemisinin resistant versus sensitive strain warrant early termination reporting study .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>Male female , age 6 month old Acute severe P. falciparum malaria another indication treat IV artesunate . Defined one following , occur absence identify alternative cause , presence P. falciparum asexual parasitaemia : Prostration OR obtundation BCS &lt; 3 ( preverbal child ) GCS &lt; 11 ( adult ) Convulsion last 24 hour Suspected acidosis , manifest acidotic breathing Respiratory distress manifest clinically ( nasal flaring/indrawing ) oxygen saturation &lt; 92 % respiratory rate &gt; 30/min History anuria Jaundice and/or hemoglobinuria Hemoglobin &lt; 7 g/dl hematocrit &lt; 20 % Significant bleeding include recurrent prolong bleed nose gum venipuncture sit ; hematemesis melena Shock define systolic blood pressure &lt; 70 mm Hg ( child ) OR &lt; 80 mm Hg ( adult ) P. falciparum parasitaemia &gt; 10 % Indication parenteral antimalarial treatment ( assessed clinician ) nausea vomit . These may include laboratory finding : Creatinine &gt; 2.5 mg/dL ( &gt; 220uM/L ) blood urea &gt; 56mg/dL ( &gt; 20 mM/L ) Glucose &lt; 4.0 mmol/L ( &lt; 72mg/dL ) Bilirubin &gt; 3 mg/dL ( &gt; 50uM/L ) Hemoglobin &lt; 7g/dL Hematocrit &lt; 20 % P. falciparum parasitaemia &gt; 4 % Venous plasma lactate &gt; 5 mM , Base deficit &gt; 8meq/L bicarbonate &lt; 15mM Written informed consent consent locally accept representative case patient render incapable provide consent due illness History 2 dose parenteral antimalarial treatment previous 24 hour History allergy know contraindication artemisinins</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Treatment Efficacy</keyword>
	<keyword>drug resistance</keyword>
	<keyword>Artemisinin</keyword>
</DOC>